FASN and neoplasm: Although the new FASN inhibitors TVB-2640, TVB-3664, TVB-3166, TVB-3664, and TVB-3166 showed high specificity and superior anti-tumor activity as specific FASN inhibitors [15,16,17], their clinical research is still in the early stages, and have not been broadly applied in tumor therapy.